GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Maze Therapeutics Inc
The stock price of Maze Therapeutics, a biotech company using genetics to develop drugs, reflects the potential of its scientific platform. Its price trajectory is a venture bet that its target-finding approach will lead to breakthrough treatments for rare diseases.
Share prices of companies in the market segment - Dna
The stock of Maze, a biotech developing drugs to treat genetically determined diseases, reflects the potential of its scientific platform. We classify it as part of the DNA sector, and the chart below reflects the dynamics of this entire segment, driven by news of clinical trials and breakthroughs in genetics.
Broad Market Index - GURU.Markets
Maze Therapeutics is a biopharmaceutical company that uses genetics and data analysis to develop targeted therapies for rare diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Maze shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MAZE - Daily change in the company's share price Maze Therapeutics Inc
For Maze Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its platform. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Dna
Maze Therapeutics Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with MAZE's dynamics, which depend on clinical trial results, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Maze is a biopharmaceutical company that uses genetics to develop drugs. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Maze's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Maze Therapeutics Inc
Maze is a biotech company developing RNA interference-based drugs. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamic of the innovation sector.
Annual dynamics of market capitalization of the market segment - Dna
Maze Therapeutics, a private biotech company, uses genetics to develop drugs. Its growth depends on the success of its scientific platform, not on market cycles. Its valuation dynamics reflect investors' faith in its ability to deliver breakthroughs, potentially outperforming the overall pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Maze Therapeutics is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Maze Therapeutics Inc
Maze, a biotech company using genetics to discover and develop new drugs, has sharp monthly fluctuations reflecting news about progress in its research programs, which is typical for preclinical companies.
Monthly dynamics of market capitalization of the market segment - Dna
Biotech companies targeting genetically determined diseases are at the cutting edge of science, driven by research data rather than profits. The chart below shows the volatility typical of this sector, reflecting investors' faith in scientific breakthroughs. This is the environment in which companies like Maze Therapeutics are pursuing new drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Maze Therapeutics, a biopharmaceutical company focused on genetically determined diseases, operates by the laws of science. Its stock price is driven by research results, not market cycles. Its performance is completely disconnected from general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Maze Therapeutics Inc
Short-term fluctuations in Maze Therapeutics, an early-stage biotech, are entirely dependent on scientific developments. Any data from preclinical or early clinical trials can trigger extreme stock movements, reflecting the high risks and potential rewards.
Weekly dynamics of market capitalization of the market segment - Dna
Maze Therapeutics shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like Maze Therapeutics often exist in their own world, isolated from broader market fluctuations. Their stocks' fortunes are determined not by inflation reports, but by clinical trial results. This chart shows how often unique company news allows its shares to move against the broader market tide.
Market capitalization of the company, segment and market as a whole
MAZE - Market capitalization of the company Maze Therapeutics Inc
Maze Therapeutics' market capitalization chart visualizes the hopes for treating rare genetic diseases. It reflects investor valuations of the company's scientific platform focused on discovering new drugs. Its speculative dynamics are a classic example of early-stage biotech, where value is determined by the potential for future discoveries rather than current revenue.
MAZE - Share of the company's market capitalization Maze Therapeutics Inc within the market segment - Dna
Maze Therapeutics is a biotech company using genetics and big data analytics to discover new drugs for rare diseases. Its market share is based on the potential of its innovative platform. The chart shows how the market values its ability to translate genetic discoveries into effective treatments.
Market capitalization of the market segment - Dna
Maze Therapeutics uses genetics to develop drugs for rare diseases. The chart below shows the overall value of the DNA analysis sector. Its growth reflects a bet that genome sequencing will be the key to the medicine of the future. Maze is blazing a trail in this scientific quest.
Market capitalization of all companies included in a broad market index - GURU.Markets
Genetic-based drug development is the future of pharmaceuticals, driving valuation. Maze Therapeutics uses genetic data to discover new targets for treating rare diseases. Its valuation is a risky bet on its scientific platform and potential for creating breakthrough drugs.
Book value capitalization of the company, segment and market as a whole
MAZE - Book value capitalization of the company Maze Therapeutics Inc
Maze Therapeutics' chart represents capital for genetic discoveries. The company's book value, which is in the research stage, is primarily made up of cash raised from investors. It uses these financial assets to invest in expensive R&D to find cures for genetically determined diseases.
MAZE - Share of the company's book capitalization Maze Therapeutics Inc within the market segment - Dna
Maze Therapeutics, a biotech company, focuses on genetically determined diseases. Its stake in the sector lies in its cutting-edge laboratories and R&D centers. The company is currently building a scientific and intellectual base that will serve as the foundation for future drugs.
Market segment balance sheet capitalization - Dna
Maze Therapeutics is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Maze focuses on genetically determined diseases, and its capital is the intellectual property of its drug discovery platform.
Book value of all companies included in the broad market index - GURU.Markets
Maze Therapeutics is a biotech company using genetics to create new drugs. Its book value is derived from investments in its scientific platform, cutting-edge laboratory equipment, and clinical trials. This is real capital invested in breakthrough research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Maze Therapeutics Inc
Maze Therapeutics is an early-stage biotech company. Its book value is primarily cash on hand. Its market capitalization is a premium to that cash, essentially representing investors' bet that its scientific platform will lead to a successful drug.
Market to book capitalization ratio in a market segment - Dna
Maze Therapeutics develops drugs based on genetic research. Like many biotech companies, its value is determined by the potential of scientific discoveries, not by its tangible assets. The chart shows the high market valuation of its intellectual property compared to its book value at an early stage.
Market to book capitalization ratio for the market as a whole
Maze Therapeutics is a biotech company using genetics to develop targeted therapies for rare diseases. Compared to average market valuations, as shown in this chart, its high premium is based on the potential of its scientific platform. Investors are betting on future discoveries rather than current assets.
Debts of the company, segment and market as a whole
MAZE - Company debts Maze Therapeutics Inc
Maze Therapeutics is a biotech company developing drugs based on genetic research. At the clinical trial stage, such companies have no revenue and are entirely dependent on external funding. The graph below shows how the company uses raised capital, including potential debt, to finance expensive R&D.
Market segment debts - Dna
Maze Therapeutics is an early-stage biotech company developing genetically-based drugs. Such companies are typically unprofitable and rely entirely on equity financing or partnerships. Significant debt is unusual. This chart helps assess the company's financial strategy for funding its expensive research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Maze Therapeutics Inc
Maze Therapeutics develops drugs based on genetic research, which requires long-term and risky investments. This chart shows the company's reliance on debt financing. High debt is a serious risk for an early-stage biotech company, as success depends on clinical trial results, not stable revenue.
Market segment debt to market segment book capitalization - Dna
Maze Therapeutics develops drugs based on genetic research, which requires massive and long-term investments in R&D. This chart shows the collective debt load in the biotech sector. It allows investors to understand how the company finances its expensive research and how its approach to debt is typical for the industry at this stage.
Debt to book value of all companies in the market
Maze Therapeutics Inc. is a biotech company developing drugs based on genetic research. During the clinical trials stage, such companies are often unprofitable and require external financing. This chart shows the overall cost of capital, which influences Maze's decision to raise more expensive equity or use debt.
P/E of the company, segment and market as a whole
P/E - Maze Therapeutics Inc
For Maze Therapeutics, a clinical-stage biotech, P/E is not a meaningful metric, as it likely lacks consistent profitability. Its valuation on this chart may be arbitrary. The company's true value lies in the potential of its research and development and future drugs.
P/E of the market segment - Dna
Maze Therapeutics is a biotech company using genetics and genomics to develop new treatments for rare and common diseases. The company is in the research stage. This chart shows the average valuation for the biotech sector, reflecting overall investor sentiment toward risky but potentially breakthrough scientific platforms.
P/E of the market as a whole
Maze Therapeutics is a biotech company using genetics to develop drugs for rare diseases. Its valuation, like that of other companies at this stage, is unrelated to the general economic cycles depicted by this chart. Maze's value is determined solely by the success or failure of its scientific research and clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Maze Therapeutics Inc
Maze Therapeutics is a biotech company using genetic data to develop new treatments for rare diseases. Its value is based on expectations of future breakthroughs. This chart demonstrates investor confidence in the company's scientific platform, reflecting expectations of clinical trial success and future drug commercialization in the current stock price.
%20P%2FE%20Maze%20Therapeutics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Maze-Therapeutics-Inc&v=1772702359113 "Chart of the company's future (projected) P/E Maze Therapeutics Inc")
Future (projected) P/E of the market segment - Dna
Maze Therapeutics is a biopharmaceutical company using genetics to develop drugs for rare diseases. The chart reflects average profitability expectations in the biotech sector. Maze's position relative to this benchmark demonstrates the level of investor confidence in its unique scientific platform and the potential for future discoveries, even in early-stage research.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772702359114 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Maze Therapeutics is a biotech company focused on genetic research to develop new drugs. It's a field with high risks and potentially enormous rewards. This chart shows investor risk appetite. During periods of market optimism, capital is more willing to fund long-term, complex scientific projects like those being pursued by Maze.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702359120 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Maze Therapeutics Inc
Maze Therapeutics is a biopharmaceutical company focused on developing drugs for genetically determined diseases. Because the company is in the research stage, this graph most often reflects net losses, which are comprised of R&D expenses. Future profits depend on the success of clinical trials.
Profit of companies in the market segment - Dna
Maze Therapeutics develops drugs based on genetic research aimed at treating rare diseases. The company's success, like many in biotech, depends on the results of clinical trials and partnerships. The data in the graph reflects the overall profitability of its segment, demonstrating the willingness of investors to fund innovation and how the sector as a whole manages R&D risks.
Overall market profit
Maze Therapeutics develops drugs based on human genetics, which requires significant and long-term investment. The overall market situation, reflected in the profitability chart, directly impacts the availability of capital for the biotech sector. During periods of growth, investors are more willing to invest in risky but promising projects, providing Maze with resources for research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Maze Therapeutics Inc
Maze Therapeutics develops genetically-based drugs for the treatment of rare diseases. The company's future profitability depends entirely on the success of clinical trials and the commercialization of its drugs. This chart shows analyst expectations, which are essentially a bet on the scientific and commercial success of Maze's innovative approach to drug development.
%20profit%20of%20the%20company%20Maze%20Therapeutics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Maze-Therapeutics-Inc&v=1772702359138 "Graph of future (projected) profit of the company Maze Therapeutics Inc")
Future (predicted) profit of companies in the market segment - Dna
Maze Therapeutics is a biotech company developing genetically-based drugs for the treatment of rare diseases. Its future depends on successful clinical trials and scientific breakthroughs. This chart reflects profitability forecasts for the entire biotech sector, allowing us to assess Maze's potential in the context of a high-risk yet promising industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772702359144 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Maze Therapeutics develops drugs based on genetic research. Like many early-stage biotech companies, its value is less dependent on the current economic cycles shown in the chart. The key factors are clinical trial success and scientific breakthroughs, rather than overall corporate profits.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702359146 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Maze Therapeutics Inc
Maze Therapeutics is a biotech company focused on genetically determined diseases. Being in the research stage, it may generate limited revenue from partnerships. The chart shows the significant premium investors are paying for its scientific potential, reflecting the hopes for breakthrough drugs based on its platform.
P/S market segment - Dna
Maze Therapeutics develops genetically based drugs for rare diseases. While the company is in the research phase, its future revenue depends on the success of clinical trials. This chart compares investor expectations for its scientific platform with those of other early-stage biotech companies.
P/S of the market as a whole
Maze Therapeutics is a biotech company using genetics to develop drugs for rare diseases. Its revenue is currently nonexistent or minimal, as all projects are in the research stage. This market revenue valuation chart helps understand how far expectations of future breakthroughs can deviate a company's valuation from its current financial performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Maze Therapeutics Inc
Maze Therapeutics is a biotech company developing genetically based drugs for the treatment of rare diseases. Its future revenue depends on the success of clinical trials. This chart shows how the market evaluates the company's scientific potential, effectively betting on the future commercial success of its drug candidates.
%20P%2FS%20Maze%20Therapeutics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Maze-Therapeutics-Inc&v=1772702359175 "The graph of the company's future (projected) P/S Maze Therapeutics Inc")
Future (projected) P/S of the market segment - Dna
Maze Therapeutics is a biopharmaceutical company using human genetics to develop precision medicines for rare and common diseases. The company's development-stage valuation is based on investors' confidence in its scientific platform and the potential of its candidates to solve complex medical problems, which carries high risks.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772702359184 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Maze Therapeutics Inc. is a biotech company using genetics to develop new drugs. Its value is based on the potential for future discoveries. In the overall revenue growth picture illustrated by the chart, Maze represents a sector where market capitalization reflects future, rather than current, revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702359186 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Maze Therapeutics Inc
Maze Therapeutics is a biotech company focused on developing drugs for genetically determined diseases. Because the company is in the research stage, its revenue, if reflected in the chart, likely comes from strategic partnerships, licensing agreements, or grants, rather than from sales of commercial products.
Sales of companies in the market segment - Dna
Maze Therapeutics (MAZE) is a biotech company that uses genetics and big data analytics to develop drugs for rare diseases. Their COMPASS platform enables the discovery of new therapeutic targets. The performance presented here reflects the total revenue of the DNA research sector, where Maze contributes by developing next-generation therapeutics.
Overall market sales
Maze Therapeutics develops genetically based drugs targeting rare diseases. While its business depends on scientific breakthroughs, the overall economic picture matters. Steady economic growth, as seen in the chart, is driving capital into the biotech sector, allowing companies like Maze to fund lengthy and expensive clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Maze Therapeutics Inc
Maze Therapeutics is a biotech company using genetics to develop drugs for rare diseases. Its future revenue depends on the success of clinical trials and the commercialization of its drugs. This chart reflects analyst forecasts, which essentially assess the likelihood of success for their research and the potential market size for future drugs.
%20sales%20of%20the%20company%20Maze%20Therapeutics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Maze-Therapeutics-Inc&v=1772702359206 "Schedule of future (projected) sales of the company Maze Therapeutics Inc")
Future (projected) sales of companies in the market segment - Dna
Maze Therapeutics is a biopharmaceutical company using genetics to develop targeted therapies. The forecast on this chart reflects potential future revenue from their programs in development. This is an analyst's view of the commercial prospects of their innovative approach to treating genetically determined diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772702359210 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Maze Therapeutics is a biotech company using genetics to develop targeted therapies for rare and common diseases. Its value is based on the potential for scientific breakthroughs. This chart, reflecting overall market sentiment, influences the availability of capital and investor willingness to fund long-term scientific research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702359212 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Maze Therapeutics Inc
Maze Therapeutics uses genetics and big data analysis to develop drugs for rare diseases. Like many early-stage biotech companies, its financial performance reflects significant investment in research. The chart shows the current state of profitability, which will depend on the success of clinical trials and the launch of its drugs.
Market segment marginality - Dna
Maze Therapeutics is a biopharmaceutical company using genetics and genomics to develop new treatments for rare diseases. This chart reflects its operating efficiency during the R&D phase. While the company has no commercial products, the metric will be negative, but its dynamics are important for assessing cost control.
Market marginality as a whole
Maze Therapeutics develops drugs based on genetic research, which requires significant and long-term investment. This graph of overall market returns reflects investors' risk appetite. During periods of high margins and economic growth, investors are more willing to fund innovative but risky biotech projects like those of Maze.
Employees in the company, segment and market as a whole
Number of employees in the company Maze Therapeutics Inc
Maze Therapeutics is a biotech company focused on developing drugs for genetically determined diseases. Its staff consists primarily of research scientists. The team's growth in this graph directly reflects the progress of the R&D pipeline: the more promising molecules, the more specialists are needed to study them.
Share of the company's employees Maze Therapeutics Inc within the market segment - Dna
Maze Therapeutics uses human genetics to develop new drugs. At this stage of the biotech's development, its greatest asset is its scientific team. This graph shows the amount of human intellect and research effort the company is investing in deciphering the genetic causes of diseases, a key indicator of its scientific potential.
Number of employees in the market segment - Dna
Maze Therapeutics develops drugs based on genetic research. This chart, which shows employment in DNA research and gene therapy, highlights the industry's talent pool. This is critical for Maze, as the company's success directly depends on its ability to attract and retain leading geneticists and bioinformaticians in a highly competitive environment.
Number of employees in the market as a whole
Maze Therapeutics is a biotech company working on the treatment of genetically determined diseases. Its staff consists of highly specialized scientists. Hiring is driven by research progress rather than general trends, but it competes for the best minds across the entire labor market, as illustrated here.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Maze Therapeutics Inc (MAZE)
Maze Therapeutics is a biotech company using genetics to develop drugs for rare and common diseases. Its entire capital comes from research and development and intellectual property. This metric clearly demonstrates how the market evaluates the potential of scientific discoveries: a huge capitalization is generated by a small team of brilliant scientists.
%20of%20the%20company%20Maze%20Therapeutics%20Inc%20(MAZE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Maze-Therapeutics-Inc-MAZE&v=1772702359253 "Chart of market capitalization per employee (in thousands of dollars) of the company Maze Therapeutics Inc (MAZE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Maze Therapeutics develops drugs based on genetic research. In biotech, market capitalization reflects the potential of scientific discoveries, not current sales or staff. This chart shows the enormous future value the market places on the work of each company scientist who has the potential to create a blockbuster drug.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772702359254 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Maze Therapeutics is a biotech company developing genetically-based drugs. The chart reflects the market valuation at an early stage of research. The company's entire value is derived from the hopes for future discoveries by its small but highly skilled team of scientists. This metric demonstrates how the market values intellectual potential, not current revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702359260 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Maze Therapeutics Inc (MAZE)
Maze Therapeutics is a biotech company using genetics to discover new drugs. During the R&D phase, profits are likely negative. This chart doesn't show revenue, but rather the "burn rate" of capital per scientist. This reflects the scale of investment in breakthrough research. Investors look to this metric in anticipation of future breakthroughs.
%20Chart%20Maze%20Therapeutics%20Inc%20(MAZE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Maze-Therapeutics-Inc-MAZE&v=1772702359261 "Company Profit Per Employee (in thousands of dollars) Chart Maze Therapeutics Inc (MAZE)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Maze Therapeutics is a biotech company developing drugs for genetically determined diseases. During the R&D phase, this metric is almost always negative (loss per employee). This chart shows how intensively the company burns through research capital per scientist while advancing drugs to the clinical trials stage.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772702359264 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Maze Therapeutics is a biotech company using genetics and genomics to develop new drugs. At this stage, it's purely R&D. The company spends heavily on research and employs highly qualified scientists. Profits are generally nonexistent. This chart is important to understand: in biotech, employee performance is based not on current profits, but on the potential of the intellectual property being created.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702359266 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Maze Therapeutics Inc (MAZE)
Maze Therapeutics is a biotech company using genetics to develop drugs for rare diseases. Being in clinical development, it has no commercial revenue yet. This chart will show zero or minimal values, which is typical for R&D companies whose value lies in the potential of their scientific discoveries.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Maze-Therapeutics-Inc-MAZE&v=1772702359268 "Sales chart per company employee Maze Therapeutics Inc (MAZE)")
Sales per employee in the market segment - Dna
Maze Therapeutics (MAZE) is a biotech company using genetics and genomics to develop drugs for genetically determined diseases. This chart shows the average revenue per employee in the sector. While this may be low for an early-stage biotech, its dynamics are important for assessing R&D efficiency compared to competitors.
Sales per employee for the market as a whole
Maze Therapeutics (MAZE) is a biotech company focused on translational genetics to develop new treatments. Being in the R&D stage, the company likely has minimal revenue (from partnerships) and a significant staff of highly qualified scientists. This metric reflects current personnel costs relative to revenue. A sharp increase in this metric in the future would indicate successful commercialization of their scientific discoveries.
Short shares by company, segment and market as a whole
Shares shorted by company Maze Therapeutics Inc (MAZE)
Maze Therapeutics (MAZE) is a biotech company using genetics to develop new treatments. Like many early-stage companies, its stock is highly speculative. This chart shows the volume of short bets. High levels of short bets are normal for biotech, reflecting the risk that their scientific hypotheses will not be borne out in expensive clinical trials. (341)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Maze-Therapeutics-Inc-MAZE&v=1772702359282 "Short Shares Chart for the Company Maze Therapeutics Inc (MAZE)")
Shares shorted by market segment - Dna
Maze Therapeutics uses genetics and AI to discover new drugs for rare diseases (such as Pompe disease). This chart reflects the overall sentiment in the sector. It reflects the high investor skepticism toward early-stage biotech companies, which are entirely dependent on the success of clinical trials.
Shares shorted by the overall market
Maze Therapeutics is an early-stage biotech company using genetics to discover new drugs. Its value represents the hope for a future breakthrough. When this market fear indicator rises, investors are unwilling to hold out hope. They sell off unprofitable, speculative biotechs like Maze en masse to invest in assets that generate profits in the here and now.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Maze Therapeutics Inc (MAZE)
Maze Therapeutics (MAZE) is a biotech company that uses genetics and data analytics to discover new drug targets for rare and common diseases. It is an R&D platform. This chart measures hype. It shows "overbought" (above 70) during news of partnerships or research breakthroughs, and "oversold" (below 30) during periods of no news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Maze-Therapeutics-Inc-MAZE&v=1772702359287 "RSI 14 indicator chart for the company's stock Maze Therapeutics Inc (MAZE)")
RSI 14 Market Segment - Dna
Maze Therapeutics (MAZE) is a biotech company using genetics and AI to discover new treatments for rare diseases, starting with Pompe disease. This chart tracks the collective sentiment in the DNA/Genomic Technologies sector. It helps investors understand whether the entire biotech segment is overheated by the hype surrounding AI in medicine or oversold.
RSI 14 for the overall market
Maze Therapeutics (MAZE) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MAZE (Maze Therapeutics Inc)
Maze Therapeutics is a biotech company using genetics to develop precision drugs for rare diseases, beginning with kidney disease. This chart reflects the analyst consensus: their average price target for Maze shares, which depends almost entirely on the success of its R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MAZE-Maze-Therapeutics-Inc&v=1772702359297 "A chart showing analyst consensus forecasts for the expected stock price. MAZE (Maze Therapeutics Inc)")
The difference between the consensus estimate and the actual stock price MAZE (Maze Therapeutics Inc)
Maze Therapeutics is a clinical-stage biotech company using genetics and big data to discover new drug targets for rare diseases. This chart reflects analysts' speculative expectations regarding their R&D platform and the ability to bring at least one of their many early-stage projects to commercialization.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MAZE-Maze-Therapeutics-Inc&v=1772702359300 "A chart showing the difference between the consensus forecast and the actual stock price. MAZE (Maze Therapeutics Inc)")
Analyst consensus forecast for stock prices by market segment - Dna
Maze Therapeutics is a biotech company that uses human genetics to discover and develop new drugs for rare and common diseases. This chart shows analysts' overall expectations for the DNA technology sector. It reflects their belief in the success of R&D platforms based on genetic analysis.
Analysts' consensus forecast for the overall market share price
Maze Therapeutics is a biotech company using genetics and data analytics to develop drugs for rare genetic diseases. This chart shows the overall market risk appetite. For Maze, as an early-stage company, overall market optimism is critical to attracting the capital needed to fund lengthy and expensive R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Maze Therapeutics Inc
Maze Therapeutics is a biotech company using a genetic compass for drug discovery. Their platform (Compass) analyzes large data sets of human genetics to identify new targets for the treatment of rare and complex diseases, such as Pompe disease. This chart evaluates their scientific platform, reflecting the market's confidence in their R&D approach and the progress of their candidates in clinical trials.
AKIMA Market Segment Index - Dna
Maze Therapeutics (MAZE) is a clinical-stage biotech and a pioneer in genetic medicine; the company uses its platform (Compass) to discover genetic targets for the treatment of rare diseases. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D platform (MAZE) differentiate it from the average pharma company?
The AKIM Index for the overall market
Maze Therapeutics is a biotech company using genetic data to develop drugs for kidney and cardiovascular diseases. This is cutting-edge science. This chart, reflecting the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding and evaluating the prospects of such innovative companies.
